In Canada, a Public Advisory warning against the concomitant use of Paxil [paroxetine] or Paxil controlled-release (CR) and Orap [pimozide]

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1063, 2005-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

In Canada, GlaxoSmithKline has advised that the concomitant use of Paxil [paroxetine] and Orap [pimozide] is contraindicated

By  

Reactions Weekly, Vol. 1, Iss. 1062, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Congenital malformation warning added to US Paxil/Paxil CR labels

By  

Reactions Weekly, Vol. 1, Iss. 1071, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

The US FDA has recommended that paroxetine [`Paxil'] not be used in children and adolescents

By  

Inpharma, Vol. 1, Iss. 1393, 2003-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Paroxetine controlled-release: benefits in fibromyalgia

By  

Inpharma, Vol. 1, Iss. 1438, 2004-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Health Canada has approved GlaxoSmithKline's controlled-release formulation of paroxetine

By  

Inpharma, Vol. 1, Iss. 1420, 2004-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite